Literature DB >> 1505197

A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.

N Bodor1, N Bodor1, W M Wu.   

Abstract

A "Soft" corticosteroid, loteprednol etabonate I, designed based on the "inactive metabolite" concept can be used as a safe ophthalmic anti-inflammatory drug. By design, the metabolism of I follows a predicted biotransformation pathway, thus unwanted systemic side effects are avoided. Local side effects are also reduced. Accordingly, in a cross-over study I did not elevate the intraocular pressure (IOP) in rabbits, as opposed to dexamethasone.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1505197     DOI： 10.3109/02713689209001808

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN： 0271-3683            Impact factor:   2.424


  7 in total

Review 1.  Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 2.  Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  AAPS J       Date:  2005-12-07       Impact factor: 4.009

Review 3.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

Review 4.  Synthesis and pharmacology of anti-inflammatory steroidal antedrugs.

Authors:  M Omar F Khan; Henry J Lee
Journal:  Chem Rev       Date:  2008-12       Impact factor: 60.622

5.  Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.

Authors:  Timothy L Comstock; Heleen H Decory
Journal:  Int J Inflam       Date:  2012-03-28

6.  Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.

Authors:  Megan E Cavet; Shellise Glogowski; Ezra R Lowe; Eric Phillips
Journal:  J Ocul Pharmacol Ther       Date:  2019-03-23       Impact factor: 2.671

Review 7.  Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis.

Authors:  Francis S Mah; Paul M Karpecki
Journal:  Ophthalmol Ther       Date:  2021-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.